Search Results

You are looking at 1 - 10 of 4,204 items for :

  • Refine by Access: all x
Clear All
Restricted access

Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539

Leland Rogers, Peixin Zhang, Michael A. Vogelbaum, Arie Perry, Lynn S. Ashby, Jignesh M. Modi, Anthony M. Alleman, James Galvin, David Brachman, Joseph M. Jenrette, John De Groot, Joseph A. Bovi, Maria Werner-Wasik, Jonathan P. S. Knisely, and Minesh P. Mehta

, but, based on a recently published secondary endpoint analysis of pathology concordance from NRG Oncology RTOG 0539, the WHO 2000 and 2007 standards appear to have been broadly followed, at least among institutions enrolling patients in NRG Oncology RTOG cooperative group trials. 40 Several cooperative group meningioma protocols have been launched, but they either have met with disappointing results or have failed to reach accrual goals. 10 , 21 , 25 , 27 The Southwest Oncology Group (SWOG) completed a Phase III trial, with results published in 2015 by Ji and

Free access

Quantifying the utility of a multidisciplinary neuro-oncology tumor board

Adham M. Khalafallah, Adrian E. Jimenez, Carlos G. Romo, David Olayinka Kamson, Lawrence Kleinberg, Jon Weingart, Henry Brem, Stuart A. Grossman, and Debraj Mukherjee

M ultidisciplinary treatment is increasingly common in the management of oncological conditions as the care of cancer patients continues to become more complex, necessitating the coordinated efforts of a diverse team of medical specialists. 1–4 Multidisciplinary tumor boards (MDTBs), consisting of meetings in which experts from different fields discuss patient cases and offer treatment recommendations, is one way to achieve such care coordination. Previous research has examined the efficacy of MDTBs in specialties such as gynecological oncology

Free access

Introduction. Update on neuro-oncology

Howard Colman, Susan M. Chang, Michael Vogelbaum, and Priscilla Brastianos

INTRODUCTION T he field of neuro-oncology continues to evolve, with ongoing advances in technology and approaches aimed at improving the diagnosis and treatment of primary and metastatic brain and spine tumors. This progress is highlighted by the recent 2021 update of the World Health Organization Classification of Tumors of the Central Nervous System. This classification represents a significant step forward in how we classify and treat primary brain tumors, with the inclusion of molecular diagnostic criteria for many different tumor types representing a

Free access

Neuro-oncology authorship trends in gender since 1944: a systematic review of 14,020 articles from five top-tier academic journals

Rosemary T. Behmer Hansen, Ryan A. Behmer Hansen, Justin L. Gold, Sai Batchu, Rebecca D. Lozada, Samantha D. Palma, Stephen J. Susman, William A. Blocher III, and Angela M. Richardson

G ender differences in oncology and neurosurgery are well described. While the percentage of women in oncology fellowships closely mirrors the gender distribution of medical students at 48%, only 30% of practicing oncologists are female. 1 In contrast, comparatively fewer women than men enter neurosurgical residencies (less than 10% in 2008). 2 – 4 Gender differences persist at the faculty level: in 2014 only 8.8% of practicing academic neurosurgeons in the United States were female, and female neurosurgeons had lower rates of board certification than

Free access

Carbon fiber–reinforced PEEK instrumentation in the spinal oncology population: a retrospective series demonstrating technique, feasibility, and clinical outcomes

Matthew T. Neal, Alexandra E. Richards, Kara L. Curley, Naresh P. Patel, Jonathan B. Ashman, Sujay A. Vora, and Maziyar A. Kalani

-grade malignancies, recurrent tumors, or in cases in which satisfactory oncological margins cannot be achieved. 3 When surgical intervention in the spinal oncology population requires stabilization with spinal hardware, conventional implant materials can be problematic. Commonly used metallic implant materials such as titanium alloys produce substantial artifacts on imaging that interfere with proper planning and delivery of RT. The presence of metals with a high number of atomic protons in the nucleus (high-Z materials), such as titanium or cobalt, can cause severe artifacts on

Restricted access

Treatment of intramedullary spinal cord tumors: a modified Delphi technique of the North American Spine Society Section of Spine Oncology

Presented at the 2023 AANS/CNS Joint Section on Disorders of the Spine and Peripheral Nerves

Andrew M. Hersh, Zach Pennington, Daniel Lubelski, Aladine A. Elsamadicy, Nicolas Dea, Atman Desai, Ziya L. Gokaslan, C. Rory Goodwin, Wesley Hsu, George I. Jallo, Ajit Krishnaney, Ilya Laufer, Sheng-Fu Larry Lo, Mohamed Macki, Ankit I. Mehta, Ali Ozturk, John H. Shin, Hesham Soliman, and Daniel M. Sciubba

80%–100% agreement for a particular treatment option were considered sufficient for consensus, while responses with 70%–79% agreement were defined as agreement in accordance with the methodology of Dammann et al. 10 Preferences with < 70% agreement were considered disputed. The responses were summarized and analyzed using Microsoft Excel. Results Demographics of the 14 included spinal oncology experts are illustrated in Table 1 . Eleven (79%) completed dedicated spinal oncology fellowships, 13 (93%) practiced at centers associated with designated regional

Restricted access

High-volume facilities are not always low risk: comparing risk-standardized mortality rates versus facility volume as quality measures in surgical neuro-oncology

Eric J. Chalif, Jacob S. Young, Genaro R. Villa, Manish K. Aghi, Jacopo Lenzi, and Mitchel S. Berger

effective and efficient than facility volume in improving care centralization for a number of common cancer types, including lung, colorectal, and others. 14 , 15 However, the utility of RSMR as a performance indicator is currently unknown for tumors of the CNS. The goal of this study was to evaluate RSMR compared with facility volume as performance indicators in surgical neuro-oncology. The primary outcome of this study was modeling the number of patients who would need to be moved from a low-performing hospital to a high-performing hospital in order to save one life

Restricted access

Cross-cultural adaptation, reliability, and validity of the Russian version of the Spine Oncology Study Group Outcomes Questionnaire (SOSGOQ2.0)

Nikita Zaborovskii, Anton Denisov, John Shapton, Adam Schlauch, Dmitrii Ptashnikov, Sergei Masevnin, Oleg Smekalenkov, Vladislav Murakhovsky, Pavel Mytyga, and Dimitriy Kondrashov

, the most validated HRQOL questionnaire specific to the metastatic spine cancer population is the Spine Oncology Study Group Outcomes Questionnaire (SOSGOQ), 8 , 10 which was recently updated to its second version (SOSGOQ2.0). 11 The SOSGOQ2.0 contains questions that assess physical function, neurological function, pain, mental health, social function, and perceived effects of therapy on a Likert scale of 1–5. 8 It has been well validated in the English language. 11 As the number of multinational and multicultural research projects involving the spinal

Free access

The 100 most-cited articles in spinal oncology

Rafael De la Garza-Ramos, Mario Benvenutti-Regato, and Enrique Caro-Osorio

I n the last decades, spinal oncology has emerged as a separate subspecialty, 114 reflecting years of research focused on innovative techniques for controlling spinal tumors and managing the pain and pathophysiology arising from these types of cancers. 84 Although management of some diseases may involve few specialists, patients with spinal tumors are usually treated by a multidisciplinary team, including neurosurgeons, orthopedic surgeons, oncologists, radiation oncologists, and neurologists. 84 Thus, the spinal oncology literature encompasses numerous

Restricted access

Incidence and severity of postoperative cerebellar mutism syndrome in children with medulloblastoma: a prospective study by the Children’s Oncology Group

Patricia L. Robertson, Karin M. Muraszko, Emiko J. Holmes, Richard Sposto, Roger J. Packer, Amar Gajjar, Mark S. Dias, and Jeffrey C. Allen

.1007/s003810050261 67 Tait DM , Thornton-Jones H , Bloom HJ , Lemerle J , Morris-Jones P : Adjuvant chemotherapy for medulloblastoma: the first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I) . Eur J Cancer 26 : 464 – 469 , 1990 68 Turgut M : Transient “cerebellar” mutism . Childs Nerv Syst 14 : 161 – 166 , 1998 10.1007/s003810050204 69 Van Calenbergh F , Van de Laar A , Plets C , Goffin J , Casaer P : Transient cerebellar mutism after posterior fossa surgery in children